Anavex Life Sciences Corp (AVXL)

[georgejjl]

Subjects with no Down Titration, n (%)
Those taking placebo 166 ( 98.8%)
Those target to take either 30 mg or 50 mg of blarcamesine per day 263 ( 78.5%)

78.5% of participants in the Phase 2b/3 trial had no issues with titration to the target dose.

GOD bless,